TABLE 7.
SUCRA values of different groups for outcomes.
| The clinical effectiveness rate (%) | Performance status | CD3+ | CD4+ | CD8+ | CD4+/CD8+ | Gastrointestinal reactions | Leukopenia | Platelet decline | Nausea and vomitting | |
|---|---|---|---|---|---|---|---|---|---|---|
| ADI + XELOX | 39.9 | 35.0% | 32.8% | 31.7% | 25.6% | 36.7% | 43.1% | 40.6% | 48.5% | 61.1% |
| SQFZI + XELOX | 70.3 | 48.8% | 71.3% | 85.5% | 56.6% | 63.6% | 86.1% | 87.5% | 70.5% | — |
| SMI + XELOX | 76.8 | 80.8% | — | — | — | — | — | — | 58.9% | 57.2% |
| KAI + XELOX | 42.5 | 41.1% | — | — | — | — | 85.7% | 30.5% | 34.1% | 46.4% |
| KLTI + XELOX | 75.6 | 55.3% | — | — | — | 92.8% | — | 61.5% | 26.7% | 49.6% |
| MI + XELOX | 14.1 | — | 43.9% | 58.0% | 20.9% | 64.6% | 73.5% | — | — | 28.4% |
| SMYI + XELOX | 91.8 | — | 100.0% | 73.1% | 0.2% | — | — | — | — | — |
| CI + XELOX | 50.4 | — | 69.7% | 53.3% | 97.4% | 90.8% | — | 48.8% | 73.1% | 80.8% |
| BJOI + XELOX | 32.5 | 51.4% | 30.3% | 58.8% | 88.2% | 24.6% | — | — | — | — |
| CKSI + XELOX | 50.0 | — | — | 38.9% | 39.8% | 26.4% | 39.5% | 76.6% | 76.7% | 67.2% |
| XAPI + XELOX | 48.0 | 87.6% | — | — | — | — | 11.4% | — | — | — |
| XELOX | 7.0 | 0.1% | 2.0% | 0.7% | 71.3% | 0.4% | 10.7% | 4.6% | 11.5% | 9.2% |
The values in bold are values with statistical analysis significance.